Healthy Volunteer Clinical Trial
Official title:
A Single-centre, Parallel-cohort, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects in the Fed State.
Verified date | April 2022 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To assess the bioequivalence between dapagliflozin/metformin XR FDC tablet and co-administration of dapagliflozin and metformin XR tablets.
Status | Completed |
Enrollment | 80 |
Est. completion date | June 14, 2021 |
Est. primary completion date | June 14, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures. 2. Healthy Chinese subjects as determined by no clinically significant deviation from normal in medical history, vital signs, physical examination, 12-lead ECG, and clinical laboratory evaluations. 3. Male or female, ages 18 to 55 years, inclusive, at the time of signing the informed consent 4. Weigh at least 50 kg (for male) and 45 kg (for female), respectively, and have a body mass index (BMI) = 19 and <26 kg/m2. BMI = weight (kg)/[height (m)]2. 5. Female participants: Women of childbearing potential must use one highly effective form of birth control. 6. Must be able to communicate with the investigator, understand and comply with all study requirements. Exclusion Criteria: 1. Any significant acute or chronic medical illness. 2. Current or recent (within 3 months prior to study drug administration) gastrointestinal disease that may impact drug absorption and affect PK of the study drugs. Additionally, any gastrointestinal surgery (eg, partial gastrectomy, pyloroplasty) that could impact the absorption of study drug. 3. Any major surgery, as determined by the investigator, within 4 weeks prior to study drug administration. 4. Donation of blood within 3 months prior to study drug administration. 5. Blood transfusion within 4 weeks prior to study drug administration. 6. Inability to tolerate oral medication. 7. Inability to tolerate venous access. 8. Drug or alcohol abuse within 6 months prior to study drug administration. Alcohol abuse is defined as a history of regular alcohol consumption exceeding 14 drinks per week, or a positive breath alcohol test at screening and/or check-in. 1 drink equals to 5 ounces (150ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of hard liquor. 9. Regularly drink more than 3 cups of coffee or other caffeine-containing products a day, or 5 cups of tea a day. 10. Regular smoker (the subject should be able to abstain from smoking for the duration of the study without having abstinence, therefore they should not be regular smokers, regular smokers are defined as people who smoke everyday), use of tobacco-containing or nicotine-containing products (including but not limited to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or nicotine gum) within 4 weeks prior to study drug administration . 11. Any other sound medical, psychiatric and/or social reason as determined by the investigator. 12. Any of the following on ECG prior to study drug administration: 1. PR=210ms 2. QRS=120ms 3. QT=500ms 4. QTcF=450ms(male) or QTcF=470ms(female) 13. Positive urine screen for drugs of abuse. 14. Any clinically significant abnormal findings in urinalysis (may repeat once) at screening, as judged by the investigator. 15. Glucosuria at screening. 16. Abnormal liver function tests (alanine aminotransferase [ALT], aspartate aminotransferase [AST], or total bilirubin > 10% above upper limit of normal [ULN]). 17. Elevated serum creatinine (> ULN). 18. Positive blood screen for HIV antibody , Syphilis antibody, hepatitis C antibody , or Hepatitis B surface antigen (HbsAg) or only Hepatitis B core antibody (anti-HBc) in Hepatitis B serologic test. 19. History of allergy to SGLT2 inhibitor drug class or related compounds. 20. History of allergy or intolerance to metformin or other similar acting agents. 21. History of any significant drug allergy (such as anaphylaxis or hepatotoxicity). 22. Prior exposure to metformin or dapagliflozin within 3 months of study drug administration. 23. Exposure to any investigational product or placebo within 4 weeks prior to study drug administration. 24. Use of any prescription drugs or over-the counter (OTC), traditional Chinese medicine and herbal preparations within 4 weeks prior to study drug administration. 25. Involvement in the planning and/or conduct of the study (applies to AstraZeneca staff or staff at the study site). 26. Previous enrolled or randomized in the present study. 27. For women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding. 28. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 29. Has clinical signs and symptoms consistent with COVID-19 infection (eg fever, dry cough, dyspnea, sore throat, fatigue.. etc) as judged by investigator or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission. 30. History of COVID-19. |
Country | Name | City | State |
---|---|---|---|
China | Research Site | Suzhou |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Haematology and clinical chemistry laboratory variables over time - SI unit - Change from baseline | To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state. | Day 2 and Day 4 in Treatment period 1 and 2, respectively. | |
Other | Vital signs over time - Change from baseline | To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state. | From Day 2 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Other | ECG variables over time - Change from baseline | To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state. | Day 1, 4 hours and 8 hours after dosing and Day 4 in Treatment period 1 and 2, respectively. | |
Other | Urinalysis data over time | To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state. | Day 2 and Day 4 in Treatment period 1 and 2, respectively. | |
Other | Incidence of adverse events | To further assess the safety and tolerability of dapagliflozin/metformin XR FDC and coadministration of the individual components in healthy Chinese subjects in the fed state. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Primary | Area under the plasma concentration-time curve from zero to the last quantifiable concentration(AUClast) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Primary | Area under the plasma concentration-time curve from zero to infinity (AUCinf) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Primary | Maximum observed plasma concentration (Cmax) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Secondary | Time to maximum observed plasma concentration (tmax) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Secondary | Terminal elimination rate constant (?z) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Secondary | Half-life associated with terminal slope of a semi-logarithmic concentration-time curve(t½?z) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Secondary | Apparent total body clearance of drug from plasma after extravascular administration (CL/F) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. | |
Secondary | Apparent volume of distribution following extravascular administration (Vz/F) of dapagliflozin and metformin. | For period 1 and 2, PK samples will be collected pre-dose and 0.5,1,2,3,4,6,8,10,12,24(Day2),36,48(Day3), and 72(Day4) hours post dose. | From Day 1 to Day 4, in Treatment period 1 and 2, respectively. An average of 11 to 18 days. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01414881 -
Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01433575 -
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
|
Phase 1 | |
Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 |